CA2661172A1 - Programmable buoyant delivery technology - Google Patents

Programmable buoyant delivery technology Download PDF

Info

Publication number
CA2661172A1
CA2661172A1 CA002661172A CA2661172A CA2661172A1 CA 2661172 A1 CA2661172 A1 CA 2661172A1 CA 002661172 A CA002661172 A CA 002661172A CA 2661172 A CA2661172 A CA 2661172A CA 2661172 A1 CA2661172 A1 CA 2661172A1
Authority
CA
Canada
Prior art keywords
active agent
core
polymeric layer
agents
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002661172A
Other languages
English (en)
French (fr)
Inventor
Amarjit Singh
Sarabjit Singh
Shivanand Puthli
Rajendra Tandale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2661172A1 publication Critical patent/CA2661172A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002661172A 2006-09-04 2007-09-03 Programmable buoyant delivery technology Abandoned CA2661172A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1411/MUM/2006 2006-09-04
IN1411MU2006 2006-09-04
PCT/IN2007/000392 WO2008062440A2 (en) 2006-09-04 2007-09-03 Programmable buoyant delivery technology

Publications (1)

Publication Number Publication Date
CA2661172A1 true CA2661172A1 (en) 2008-05-29

Family

ID=39430167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002661172A Abandoned CA2661172A1 (en) 2006-09-04 2007-09-03 Programmable buoyant delivery technology

Country Status (16)

Country Link
US (1) US8277843B2 (https=)
EP (1) EP2068844A4 (https=)
JP (1) JP2010502591A (https=)
KR (1) KR20090065524A (https=)
CN (1) CN101511346B (https=)
AR (1) AR062644A1 (https=)
AU (1) AU2007323018B2 (https=)
BR (1) BRPI0716481A2 (https=)
CA (1) CA2661172A1 (https=)
CL (1) CL2007002562A1 (https=)
IL (1) IL197121A0 (https=)
MX (1) MX2009002371A (https=)
NO (1) NO20090807A (https=)
RU (1) RU2420268C2 (https=)
WO (1) WO2008062440A2 (https=)
ZA (1) ZA200901162B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2009153635A1 (en) * 2008-06-19 2009-12-23 University Of Witwatersrand, Johannesburg A chronotherapeutic pharmaceutical dosage form
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
JP5594484B2 (ja) * 2009-07-06 2014-09-24 杏林製薬株式会社 中空構造を有する錠剤
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110177231A1 (en) * 2010-01-16 2011-07-21 Alexander Grinberg Nano-, Micro-, Macro- Encapsulation And Release Of Materials
US20110200671A1 (en) * 2010-02-17 2011-08-18 Sun Pharma Advanced Research Company Ltd. Method of treating a disease condition susceptible to baclofen therapy
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
GB201102148D0 (en) 2011-02-08 2011-03-23 Ucl Business Plc Layered bodies, compositions containing them and processes for producing them
WO2013009186A1 (en) * 2011-07-14 2013-01-17 APET Holding B.V. Nicotinamide compositions and the therapeutic use thereof
EP2872140A1 (en) 2012-07-16 2015-05-20 APeT Holding B.V. Gastro-retentive drug delivery system
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
CN105813536A (zh) * 2013-10-22 2016-07-27 吕甘雨 用于具有多个密度相的胶囊装置的系统及方法
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
NZ727659A (en) 2014-06-11 2021-12-24 Massachusetts Inst Technology Residence structures and related methods
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en) 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
CN109310639A (zh) 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构
JP2019532947A (ja) 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
JP6957610B2 (ja) * 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
CA3066658A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
WO2019025869A1 (en) * 2017-07-31 2019-02-07 Teva Pharmaceutical Industries Limited GALENIC FORMS WITH CONTROLLED RELEASE MANUFACTURED IN ADDITIVE MANNER
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
AU2018388577B2 (en) 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
CA3097737A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CA3085941A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
JP2022544239A (ja) 2019-08-12 2022-10-17 マサチューセッツ インスティテュート オブ テクノロジー 治療薬の投与のための物品及び方法
TWI763036B (zh) * 2020-09-14 2022-05-01 王子賓 可膨脹微膠囊
KR20230170674A (ko) 2021-03-15 2023-12-19 이피토미 메디칼 엘티디 활성제를 조직으로 전달하기 위한 확장가능한 디바이스
AU2023346631A1 (en) 2022-09-21 2025-05-01 Epitomee Medical Ltd. Controllably disintegrable self-expandable ingestible devices
NL2033549B1 (en) * 2022-11-17 2024-05-28 Taiwan Mercury Medical Corp Metformin tablet for relieving pain and reducing inflammation and manufacturing method thereof
AU2024265092A1 (en) * 2023-05-03 2025-11-20 Dark Canyon Laboratories, Llc A floating drug delivery system for solid forms of salts used in bowel cleansing products
DK202430306A1 (en) * 2024-06-10 2025-12-19 Merdury Biopharmaceutical Corp Oral peptide drug structure and manufacturing method thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512411B2 (https=) * 1974-03-12 1980-04-02
JPS5134879A (en) * 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
JPH03101615A (ja) * 1989-09-14 1991-04-26 Sumitomo Pharmaceut Co Ltd 胃内滞留型持続性製剤
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
SK284813B6 (sk) * 1997-03-26 2005-12-01 Janssen Pharmaceutica N. V. Peleta obsahujúca itrakonazol, spôsob jej prípravy a farmaceutická dávková forma s jej obsahom
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6050796A (en) 1998-05-18 2000-04-18 General Motors Corporation Vane pump
WO2001058424A1 (en) * 2000-02-09 2001-08-16 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Floating drug delivery composition
JP2002370970A (ja) * 2001-06-12 2002-12-24 Sanwa Kagaku Kenkyusho Co Ltd 胃内浮遊型固形製剤及びその製造方法
JP4426286B2 (ja) * 2001-07-10 2010-03-03 テバ ファーマシューティカル インダストリーズ リミティド ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
EP1574534A1 (en) * 2004-03-11 2005-09-14 Rohm And Haas Company Polymer carriers and process

Also Published As

Publication number Publication date
CN101511346A (zh) 2009-08-19
NO20090807A (no) 2009-06-04
MX2009002371A (es) 2009-03-12
EP2068844A2 (en) 2009-06-17
IL197121A0 (en) 2009-11-18
AU2007323018A1 (en) 2008-05-29
AR062644A1 (es) 2008-11-19
WO2008062440A2 (en) 2008-05-29
ZA200901162B (en) 2010-06-30
AU2007323018B2 (en) 2011-02-03
WO2008062440A3 (en) 2008-07-31
US20100015224A1 (en) 2010-01-21
US8277843B2 (en) 2012-10-02
EP2068844A4 (en) 2013-01-23
BRPI0716481A2 (pt) 2014-03-18
JP2010502591A (ja) 2010-01-28
CL2007002562A1 (es) 2008-02-08
KR20090065524A (ko) 2009-06-22
RU2420268C2 (ru) 2011-06-10
CN101511346B (zh) 2012-07-04
RU2009112396A (ru) 2010-10-20

Similar Documents

Publication Publication Date Title
AU2007323018B2 (en) Programmable buoyant delivery technology
US11007145B2 (en) Gastroretentive dosage forms for sustained drug delivery
US12569443B2 (en) Gastro-retentive drug delivery system
ES2273790T3 (es) Composicion farmaceutica de liberacion sostenida.
CN1988891B (zh) 包衣片制剂和方法
JP5808670B2 (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
ES2203885T3 (es) Formulacion de matriz de liberacion modificada de cefaclor y cefalexina.
US20060045865A1 (en) Controlled regional oral delivery
US20080286344A1 (en) Solid form
US20080311162A1 (en) Solid form
ES2310686T3 (es) Composiciones de liberacion controlada.
JP2022104916A (ja) 自己調節性の浸透性胃保持性薬物送達システム
US20050142199A1 (en) Pharmaceutical dosage forms comprising tablet core having a tensile strength below 38 n/sqcm and a coating to protect the soft core
US20180078503A1 (en) Gastro-retentive drug delivery system
ES2408343A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
ZA200307551B (en) Timed pulse release composition.
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
EP4647130A2 (en) Pharmaceutical composition comprising eliglustat
Rahim Preparation and Characterisation of Floating Tablets to Target the Stomach
Gupta Formulation Development And Evalution Of Immediate Release Tablet of Anti Hypertensive Drug Olmesartan Medoxomile.
TR201807142A2 (tr) Doksi̇lami̇n ve pi̇ri̇doksi̇n i̇çeren enteri̇k tabletler

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140623